Table 2.
Characteristics of the case and control populations.
| Case (n = 363) | Control (n = 199) | P Value | OR (95% CI) | |
|---|---|---|---|---|
| Sex (male), n (%) | 210 (58) | 107 (55.2) | 0.5 | |
| • Missing value | 1 | 5 | ||
| Age, mean (SD) | 1.37 (1.16) | 2.21 (1.68) | <0.001 | |
| • Missing value | 1 | 8 | ||
| Number of samples collected according to month, n (%) | <0.001 | |||
| • Jan-Feb | 86 (23.7) | 36 (18.1) | ||
| • Mar-Apr | 80 (22.0) | 37 (18.6) | ||
| • May-Jun | 40 (11.0) | 50 (25.1) | ||
| • Jul-Aug | 39 (10.7) | 20 (10.1) | ||
| • Sept-Oct | 61 (16.8) | 15 (7.5) | ||
| • Nov-Dec | 57 (15.7) | 31 (15.6) | ||
| • Missing value | 0 (0) | 10 (5.0) | ||
| Positive novel HAstV, n (%)* | 23 (6.3) | 6 (3.7) | 0.30 | 1.78 (0.68–5.45) |
| • Log10 RNA copies/ml, median (IQR) | 2.54 (2.18–3.76) | 6.22 (2.81–7.66) | 0.07 | |
| Positive for MLB, n (%)* | 21 (5.8) | 4 (2.4) | 0.12 | 2.45 (0.81–9.98) |
| • Log10 RNA copies/ml, median (IQR) | 2.35 (2.13–3.76) | 6.52 (4.52–6.84) | 0.008 | |
| Positive for VA, n (%)* | 4 (1.1) | 2 (1.2) | 1.00 | 0.90 (0.13–10.07) |
| • Log10 RNA copies/ml, median (IQR) | 3.23 (2.87–8.86) | 2.70 (1.73–9.05) | 0.47 |
P value for comparison between case and control patients. *The prevalence calculated here included the period between August-May in order to appropriately compare case and control patients. RNA copies correspond to RNA copy number/ml of fecal suspension. OR: odds ratio; CI: confidence interval; IQR: interquartile range; Jan: January; Feb: February; Mar: March; Apr: April; Jun: June; Aug: August; Sept: September; Oct: October; Nov: November; Dec: December; HAstV: Human astrovirus.